Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.00 price objective on shares of Aptose Biosciences in a research note on Friday, January 10th.

Aptose Biosciences Price Performance

NASDAQ:APTO opened at $0.21 on Thursday. The firm has a market capitalization of $12.87 million, a price-to-earnings ratio of -0.07 and a beta of 0.87. The business has a 50 day simple moving average of $0.23 and a 200-day simple moving average of $0.38. Aptose Biosciences has a 1 year low of $0.13 and a 1 year high of $2.30.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp raised its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities & Exchange Commission. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.